GSK-3β (27C10) Rabbit mAb #9315
产品特性
| Product Cat#: | #9315 |
| Product type: | Primary antibody |
| Antigen: | GSK-3β |
| Immunogen: | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human GSK-3β protein. |
| Species immunized: | Rabbit |
| Isotype: | IgG |
| Applications: | Western Blotting 1:1000 |
| Immunoprecipitation 1:50 | |
| Immunohistochemistry (Paraffin) 1:100 | |
| Reactivity: | Human, Mouse, Rat, Monkey |
| Clonality (clone number): | Monoclonal, 27C10 |
| Form: | Liquid |
| Buffer: | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
| Concentration: | - mg/ml |
| Purity: | Protein A purified |
| Storage: | Aliquot and freeze at -20℃. Avoid multiple freeze/thaw cycles. |
| Alternative names: | Glycogen synthase kinase-3 beta; EC:2.7.11.26; GSK-3 beta; Serine/threonine-protein kinase GSK3B; GSK3B |
靶标信息
Constitutively active protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules, by phosphorylating and inactivating glycogen synthase (GYS1 or GYS2), EIF2B, CTNNB1/beta-catenin, APC, AXIN1, DPYSL2/CRMP2, JUN, NFATC1/NFATC, MAPT/TAU and MACF1 (PubMed:1846781, PubMed:9072970, PubMed:14690523, PubMed:20937854, PubMed:12554650, PubMed:11430833, PubMed:16484495).
Requires primed phosphorylation of the majority of its substrates (PubMed:11430833, PubMed:16484495).
In skeletal muscle, contributes to insulin regulation of glycogen synthesis by phosphorylating and inhibiting GYS1 activity and hence glycogen synthesis (PubMed:8397507).
相关文献
1、Zhou H, Zhang Q, Liu C, Fan J, Huang W, Li N, Yang M, Wang H, Xie W, Kong H. NLRP3 inflammasome mediates abnormal epithelial regeneration and distal lung remodeling in silica‑induced lung fibrosis. Int J Mol Med. 2024 Mar;53(3):25. doi: 10.3892/ijmm.2024.5349. Epub 2024 Jan 19. PMID: 38240085; PMCID: PMC10836498.
2、Jang Y, Lee H, Cho Y, Choi E, Jo S, Sohn HM, Kim BC, Ko YJ, Lim W. An LGR4 agonist activates the GSK‑3β pathway to inhibit RANK‑RANKL signaling during osteoclastogenesis in bone marrow‑derived macrophages. Int J Mol Med. 2024 Jan;53(1):10. doi: 10.3892/ijmm.2023.5334. Epub 2023 Dec 8. PMID: 38063193; PMCID: PMC10712694.
3、Kang HW, Kim JH, Lee DE, Lee YS, Kim MJ, Kim HS, Fang S, Lee BE, Lee KJ, Yoo J, Kim HJ, Park JS. Combination therapy of niclosamide with gemcitabine inhibited cell proliferation and apoptosis via Wnt/β-catenin/c-Myc signaling pathway by inducing β-catenin ubiquitination in pancreatic cancer. Cancer Biol Ther. 2023 Dec 31;24(1):2272334. doi: 10.1080/15384047.2023.2272334. Epub 2023 Nov 2. PMID: 37917550; PMCID: PMC10623893.
